Cover Image
市場調查報告書

Silence Therapeutics plc:產品平台分析

Silence Therapeutics Plc - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 226231
出版日期 內容資訊 英文 35 Pages
訂單完成後即時交付
價格
Back to Top
Silence Therapeutics plc:產品平台分析 Silence Therapeutics Plc - Product Pipeline Review - 2015
出版日期: 2015年09月09日 內容資訊: 英文 35 Pages
簡介

Silence Therapeutics plc (原稱SR Pharma plc),是致力於重病治療用RNA干擾治療藥之開發與遞藥的生物科技企業。該公司的開發中產品,用於治療胰臟·頭部·頸椎癌症和肺部疾病。該公司同時也致力於糖尿病黃斑部水腫和老齡化性黃斑部病變,腎臟移植後內臟器官功能障礙等治療藥的開發。

本報告提供Silence Therapeutics plc的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,加上最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Silence Therapeutics Plc的基本資料

  • Silence Therapeutics Plc概要
  • 主要資訊
  • 企業資料

Silence Therapeutics Plc:R&D概要

  • 主要的治療範圍

Silence Therapeutics Plc:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Silence Therapeutics Plc:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第Ⅱ階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Silence Therapeutics Plc:藥物簡介

  • Atu-027
  • Atu-111
  • Atu-112
  • Atu-134
  • 肺動脈高血壓endosurin-1阻礙寡核甘酸
  • 肝臟疾病RNAi寡核甘酸

Silence Therapeutics Plc:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Silence Therapeutics Plc:最近的開發平台趨勢

Silence Therapeutics Plc:暫停中的計劃

Silence Therapeutics Plc:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • Atu-112

Silence Therapeutics Plc:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07563CDB

Summary

Global Markets Direct's, 'Silence Therapeutics plc - Product Pipeline Review - 2015', provides an overview of the Silence Therapeutics plc's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Silence Therapeutics plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Silence Therapeutics plc including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Silence Therapeutics plc's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Silence Therapeutics plc's pipeline products

Reasons to buy

  • Evaluate Silence Therapeutics plc's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Silence Therapeutics plc in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Silence Therapeutics plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Silence Therapeutics plc and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Silence Therapeutics plc
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Silence Therapeutics plc and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Silence Therapeutics Plc Snapshot
    • Silence Therapeutics Plc Overview
    • Key Information
    • Key Facts
  • Silence Therapeutics Plc - Research and Development Overview
    • Key Therapeutic Areas
  • Silence Therapeutics Plc - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Silence Therapeutics Plc - Pipeline Products Glance
    • Silence Therapeutics Plc - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Silence Therapeutics Plc - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Silence Therapeutics Plc - Drug Profiles
    • Atu-027
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Atu-111
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Atu-112
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Atu-134
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotide for Liver Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Silence Therapeutics Plc - Pipeline Analysis
    • Silence Therapeutics Plc - Pipeline Products by Target
    • Silence Therapeutics Plc - Pipeline Products by Route of Administration
    • Silence Therapeutics Plc - Pipeline Products by Molecule Type
    • Silence Therapeutics Plc - Pipeline Products by Mechanism of Action
  • Silence Therapeutics Plc - Recent Pipeline Updates
  • Silence Therapeutics Plc - Dormant Projects
  • Silence Therapeutics Plc - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • Atu-112
  • Silence Therapeutics Plc - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Silence Therapeutics Plc, Key Information
  • Silence Therapeutics Plc, Key Facts
  • Silence Therapeutics Plc - Pipeline by Indication, 2015
  • Silence Therapeutics Plc - Pipeline by Stage of Development, 2015
  • Silence Therapeutics Plc - Monotherapy Products in Pipeline, 2015
  • Silence Therapeutics Plc - Partnered Products in Pipeline, 2015
  • Silence Therapeutics Plc - Partnered Products/ Combination Treatment Modalities, 2015
  • Silence Therapeutics Plc - Out-Licensed Products in Pipeline, 2015
  • Silence Therapeutics Plc - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Silence Therapeutics Plc - Phase II, 2015
  • Silence Therapeutics Plc - Preclinical, 2015
  • Silence Therapeutics Plc - Pipeline by Target, 2015
  • Silence Therapeutics Plc - Pipeline by Route of Administration, 2015
  • Silence Therapeutics Plc - Pipeline by Molecule Type, 2015
  • Silence Therapeutics Plc - Pipeline Products by Mechanism of Action, 2015
  • Silence Therapeutics Plc - Recent Pipeline Updates, 2015
  • Silence Therapeutics Plc - Dormant Developmental Projects,2015
  • Silence Therapeutics Plc - Discontinued Pipeline Products, 2015
  • Silence Therapeutics Plc, Other Locations
  • Silence Therapeutics Plc, Subsidiaries

List of Figures

  • Silence Therapeutics Plc - Pipeline by Top 10 Indication, 2015
  • Silence Therapeutics Plc - Pipeline by Stage of Development, 2015
  • Silence Therapeutics Plc - Monotherapy Products in Pipeline, 2015
  • Silence Therapeutics Plc - Partnered Products in Pipeline, 2015
  • Silence Therapeutics Plc - Pipeline by Top 10 Target, 2015
  • Silence Therapeutics Plc - Pipeline by Top 10 Route of Administration, 2015
  • Silence Therapeutics Plc - Pipeline by Top 10 Molecule Type, 2015
  • Silence Therapeutics Plc - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top